 This study compares two chemotherapy regimens as adjuvant treatment for breast cancer. The study participants are randomly allocated to receive either 3 cycles of docetaxel followed by 3 cycles of CEF cyclophosphamide, epirubicin and 5-fluorouracil or to receive 3 cycles of docetaxel plus capecitabine followed by 3 cycles of CEX cyclophosphamide, epirubicin and capecitabine. The study participants are required to to have a medium to high risk for breast cancer recurrence. The primary aim of the study is to investigate whether addition of capecitabine to a standard taxaneanthracycline regimen will influence recurrence-free survival. 